SCHEMBL376784

SCHEMBL376784

CC(C)c1oc(-c2ccc(-c3ccccc3)cc2)nc1CCC(=O)c1ccc(OC(C)(C)C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 18/20 0.59
PPARG P37231 16/20 0.59
PPARD Q03181 9/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376767 0.89 PPARA (0.58) PPARAPPARGPPARD
SCHEMBL376724 0.86 PPARA (0.67) PPARAPPARGPPARD
SCHEMBL376981 0.86 PPARG (0.59) PPARAPPARGPPARD
SCHEMBL376969 0.85 PPARG (0.51) PPARAPPARGPPARD
SCHEMBL376970 0.84 PPARG (0.51) PPARAPPARGPPARD
SCHEMBL377169 0.83 PPARG (0.56) PPARAPPARGPPARD
SCHEMBL377030 0.83 PPARA (0.59) PPARAPPARGPPARD
SCHEMBL376733 0.82 PPARA (0.58) PPARAPPARGPPARD
SCHEMBL376998 0.81 PPARG (0.65) PPARAPPARGPPARD
SCHEMBL1765972 0.81 PPARA (0.69) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310494-B1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO (JP) 2012-01-25 EP disclosed
US-6787552-B2 HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2004-09-07 US disclosed
US-20040097739-A1 Ppar delta activators NIPPON CHEMIPHAR CO., LTD. (JP) 2004-05-20 US disclosed
EP-1310494-A1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097739-A1 Ppar delta activators PPARD, PPARG, PPARA PPARA 3/4885PPARG 2/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.